Tuesday, November 17, 2020

Warren Buffett Choose Pfizer And 3 Other Firms In Investments Over $ 5 Billion!

 Warren Buffett's firm Berkshire Hathaway in the third tribe has made $ 5.7 billion in investment into the stock of four pharmaceutical companies.


Following a record portfolio of $ 245 billion in equity, Berkshire has added 21.3 million shares of AbbVie, 30 million shares of Bristol-Myers Squibb, 22.4 million shares of Merck and 3.7 million shares of Pfizer.


Likewise, Buffett's investment value to the four firms is small at the end of the tribe. The new Berkshire shares include 1.3% stake in Bristol-Myers, 1.2% stake in AbbVie, 0.9% of Merck and less than 0.1% of Pfizer.


Pfizer and Merck are the firms that build the coronavirus vaccine. On the week after, Pfizer announced the order of the vaccine so that it was 90% and succeeded in achieving the highest jump in stocks to break 15% for 2020.


Overall, Berkshire's investments in the health sector have increased to $ 9.3 billion with its previous investments to top three pharmaceutical supply firms; Biogen, Johnson & Johnson, Teva Pharmaceuticals and the kidneys dialysis company, DaVita.



It was also reported that Berkshire had reduced its shares against several major banks such as Wells Fargo, JPMorgan Chase, PNC Financial and M&T Bank in the three months leading up to the end of September.


Buffett is said to have sold as much as 110.2 million shares of Well Fargo, taking ownership of that stake to just 3.1% rather than the original 10% and also selling 21.2 million shares of JPMorgan.


Prior to this the firm had made $ 6 billion in investment in over 5 Japanese companies. Berkshire shares saw a 2.3% jump this year versus 12% higher on the broad market.